Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Bryan R Haugen

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-3921

    Collapse Research 
    Collapse research activities and funding
    F32DK008796     (HAUGEN, BRYAN R)Jan 10, 1993
    NIH/NIDDK
    ISOLATION AND STUDY OF TSHB GENE TRANSCRIPTION FACTORS
    Role: Principal Investigator

    K08DK002331     (HAUGEN, BRYAN R)Jan 1, 1995 - Dec 31, 2000
    NIH/NIDDK
    PIT-1T AND THYROTROPIN BETA SUBUNIT GENE EXPRESSION
    Role: Principal Investigator

    R01DK054383     (HAUGEN, BRYAN R)Aug 15, 2000 - Jul 31, 2006
    NIH/NIDDK
    ROLE OF RETINOIDS AND RECEPTORS IN THYROTROPE FUNCTION
    Role: Principal Investigator

    R01CA100560     (HAUGEN, BRYAN R.)Mar 1, 2005 - Jul 31, 2012
    NIH/NCI
    Thiazolidinediones as Thyroid Cancer Therapy
    Role: Principal Investigator

    RC1CA147371     (FAGIN, JAMES A)Sep 30, 2009 - Aug 31, 2012
    NIH/NCI
    A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery
    Role: Co-Principal Investigator

    R01CA155512     (HAUGEN, BRYAN R.)Aug 3, 2011 - Jun 30, 2016
    NIH/NCI
    The NFkB-dependent Secretome and Invasion/Angiogenesis in Thyroid Cancer
    Role: Principal Investigator

    R01CA175994     (HAUGEN, BRYAN R.)Apr 1, 2013 - Mar 31, 2018
    NIH/NCI
    TXNIP as a Key Regulator of Thyroid Cancer Metabolism and Aggressiveness
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. French JD, Haugen BR. Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies? J Clin Endocrinol Metab. 2017 Jul 01; 102(7):2131-2132. PMID: 28899074.
      View in: PubMed
    2. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017 Jun; 27(6):751-756. PMID: 28463585.
      View in: PubMed
    3. Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. ADVERSE EVENT REPORTING IN PATIENTS TREATED WITH THYROID HORMONE EXTRACT. Endocr Pract. 2017 May; 23(5):566-575. PMID: 28225316.
      View in: PubMed
    4. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 Apr; 27(4):481-483. PMID: 28114862.
      View in: PubMed
    5. Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017 Feb 01; 123(3):372-381. PMID: 27741354.
      View in: PubMed
    6. Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 09; 7(32):51619-51625. PMID: 27322211.
      View in: PubMed
    7. Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC, Haugen BR, French JD. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2016 Jul; 101(7):2863-73. PMID: 27045886; PMCID: PMC4929840 [Available on 07/01/17].
    8. Sinclair CF, Bumpous JM, Haugen BR, Chala A, Meltzer D, Miller BS, Tolley NS, Shin JJ, Woodson G, Randolph GW. Laryngeal examination in thyroid and parathyroid surgery: An American Head and Neck Society consensus statement: AHNS Consensus Statement. Head Neck. 2016 Jun; 38(6):811-9. PMID: 26970554.
      View in: PubMed
    9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26(1):1-133. PMID: 26462967; PMCID: PMC4739132 [Available on 01/01/17].
    10. Haugen B. Editorial: Centennial Celebration: An Interview with Dr Bryan Haugen on 100 Years of Thyroid Research. Mol Endocrinol. 2016 Jan; 30(1):1-2. PMID: 26720254.
      View in: PubMed
    11. Albuja-Cruz MB, Pozdeyev N, Robbins S, Chandramouli R, Raeburn CD, Klopper J, Haugen BR, McIntyre R. A "safe and effective" protocol for management of post-thyroidectomy hypocalcemia. Am J Surg. 2015 Dec; 210(6):1162-8; discussion 1168-9. PMID: 26601651.
      View in: PubMed
    12. Patel NU, McKinney K, Kreidler SM, Bieker TM, Russ P, Roberts K, Glueck DH, Albuja-Cruz M, Klopper J, Haugen BR. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. J Clin Ultrasound. 2016 Mar-Apr; 44(3):143-51. PMID: 26402153.
      View in: PubMed
    13. McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105. PMID: 26203804; PMCID: PMC4589102 [Available on 10/01/16].
    14. Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-?B Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One. 2015; 10(8):e0134901. PMID: 26263379; PMCID: PMC4532464.
    15. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9. PMID: 26171797.
      View in: PubMed
    16. Knight M, Elhelu O, Smith M, Haugen B, Miller A, Raghavan N, Wellman C, Cousin C, Dixon F, Mann V, Rinaldi G, Ittiprasert W, Brindley PJ. Susceptibility of Snails to Infection with Schistosomes is influenced by Temperature and Expression of Heat Shock Proteins. Epidemiology (Sunnyvale). 2015 Jun; 5(2). PMID: 26504668.
      View in: PubMed
    17. Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May; 25(5):563-4. PMID: 25778496; PMCID: PMC4426316.
    18. Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun; 6(2-3):87-99. PMID: 25800363; PMCID: PMC4414894.
    19. Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC, Sams SB, Haugen BR, French JD. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015 Jun; 3(6):620-30. PMID: 25701326; PMCID: PMC4457654.
    20. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb; 100(2):E243-52. PMID: 25427145; PMCID: PMC4318904.
    21. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. J Clin Endocrinol Metab. 2014 Oct; 99(10):3487-8. PMID: 25279569.
      View in: PubMed
    22. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942- 2014. Horm Cancer. 2014 Oct; 5(5):263-4. PMID: 25200857.
      View in: PubMed
    23. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Endocr Rev. 2014 Oct; 35(5):715-6. PMID: 25247379.
      View in: PubMed
    24. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Endocrinology. 2014 Oct; 155(10):3727-8. PMID: 25238132.
      View in: PubMed
    25. Haugen BR, Wartofsky L. In memoriam, Dr. E. Chester Ridgway, 1942-2014. Mol Endocrinol. 2014 Oct; 28(10):1587-8. PMID: 25271789.
      View in: PubMed
    26. Olson AC, Haugen BR, Walter J, Kwak JJ, Bagrosky BM, Koo PJ. SPECT/CT and I131 therapy of brain metastases from follicular variant papillary thyroid carcinoma (FVPTC). J Clin Endocrinol Metab. 2014 Oct; 99(10):3511-2. PMID: 25057877.
      View in: PubMed
    27. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1436-44. PMID: 24758177; PMCID: PMC4121024.
    28. Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul; 99(7):E1368-75. PMID: 24712572.
      View in: PubMed
    29. Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014 Mar 19; 13:62. PMID: 24645981; PMCID: PMC3995095.
    30. Koo PJ, Klingensmith WC, Bagrosky BM, Haugen BR. SPECT/CT of metastatic struma ovarii. Clin Nucl Med. 2014 Feb; 39(2):186-7. PMID: 23797234.
      View in: PubMed
    31. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014 Jan; 99(1):119-25. PMID: 24152684.
      View in: PubMed
    32. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb; 24(2):232-40. PMID: 23721245.
      View in: PubMed
    33. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan; 24(1):35-42. PMID: 23731273; PMCID: PMC3887423.
    34. Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, Diggans J, Friedman L, Kennedy GC, Kloos RT, Lanman RB, Mandel SJ, Sindy N, Steward DL, Zeiger MA, Haugen BR, Alexander EK. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med. 2013 Sep 03; 159(5):325-32. PMID: 24026318.
      View in: PubMed
    35. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun; 34(3):439-55. PMID: 23575762; PMCID: PMC3660715.
    36. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013 Mar 23; 381(9871):1058-69. PMID: 23668556; PMCID: PMC3931461.
    37. Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res. 2013 Mar; 55(1-3):22-33. PMID: 22941561; PMCID: PMC3984131.
    38. Haugen BR. Radioiodine remnant ablation: current indications and dosing regimens. Endocr Pract. 2012 Jul-Aug; 18(4):604-10. PMID: 22849876.
      View in: PubMed
    39. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012 Aug 23; 367(8):705-15. PMID: 22731672.
      View in: PubMed
    40. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 01; 18(13):3580-91. PMID: 22586301; PMCID: PMC3931551.
    41. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012 Jun; 97(6):E878-87. PMID: 22496497; PMCID: PMC3387425.
    42. Haugen B, Hennessey JV, Wartofsky L. Radioactive iodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2012 Apr; 97(4):29A-30A. PMID: 22493315.
      View in: PubMed
    43. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Klopper JP, Haugen BR. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab. 2012 Jun; 97(6):E934-43. PMID: 22466343; PMCID: PMC3387418.
    44. Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR. PPAR? Promotes Growth and Invasion of Thyroid Cancer Cells. PPAR Res. 2011; 2011:171765. PMID: 22194735; PMCID: PMC3236353.
    45. Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid. 2011 Sep; 21(9):941-4. PMID: 21877921.
      View in: PubMed
    46. Haugen B, Hennessey JV, Leonard W. Patient Information Page. Medicines for hypothyroidism. J Clin Endocrinol Metab. 2011 Aug; 96(8):1, 2. PMID: 21816791.
      View in: PubMed
    47. Janssen JS, Sharma V, Pugazhenthi U, Sladek C, Wood WM, Haugen BR. A rexinoid antagonist increases the hypothalamic-pituitary-thyroid set point in mice and thyrotrope cells. Mol Cell Endocrinol. 2011 Jun 06; 339(1-2):1-6. PMID: 21458528; PMCID: PMC3112467.
    48. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec; 20(12):1423-4. PMID: 21054207.
      View in: PubMed
    49. Haugen BR, Duncan MW. Applications of proteomics to thyroid neoplasms: are we there yet? Thyroid. 2010 Oct; 20(10):1051-2. PMID: 20883170.
      View in: PubMed
    50. Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010 May 21; 9:117. PMID: 20492683; PMCID: PMC2887796.
    51. Hennessey JV, Malabanan AO, Haugen BR, Levy EG. Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the american thyroid association, american association of clinical endocrinologists, and the endocrine society. Endocr Pract. 2010 May-Jun; 16(3):357-70. PMID: 20551006.
      View in: PubMed
    52. Michels A, Haugen B. Malignant struma ovarii. J Clin Endocrinol Metab. 2010 Apr; 95(4):1505. PMID: 20375218.
      View in: PubMed
    53. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010 May; 95(5):2325-33. PMID: 20207826; PMCID: PMC2869546.
    54. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab. 2010 Mar; 95(3):987-93. PMID: 20203334.
      View in: PubMed
    55. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009 Dec; 23(6):793-800. PMID: 19942154; PMCID: PMC2784889.
    56. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov; 19(11):1167-214. PMID: 19860577.
      View in: PubMed
    57. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009 Nov; 94(11):4171-9. PMID: 19850694.
      View in: PubMed
    58. Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. PPAR Res. 2010; 2010:729876. PMID: 19859558; PMCID: PMC2763133.
    59. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8. PMID: 19772419.
      View in: PubMed
    60. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid. 2009 Aug; 19(8):825-35. PMID: 19500021; PMCID: PMC2857444.
    61. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009 Jun; 94(6):2092-8. PMID: 19318445.
      View in: PubMed
    62. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009 Jun; 94(6):2199-203. PMID: 19293266; PMCID: PMC2690419.
    63. Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer. 2009 Mar 06; 8:16. PMID: 19267912; PMCID: PMC2654861.
    64. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008 Nov; 93(11):4331-41. PMID: 18713817; PMCID: PMC2582569.
    65. Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri EL, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S, Pacini F. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008 Jul; 18(7):687-94. PMID: 18630995; PMCID: PMC2637556.
    66. Klopper J, Haugen B. Can calcitonin and carcinoembryonic antigen doubling times predict progression of thyroid carcinoma? Nat Clin Pract Endocrinol Metab. 2008 Aug; 4(8):428-9. PMID: 18542112.
      View in: PubMed
    67. Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 2008 Mar 01; 68(5):1572-80. PMID: 18316623.
      View in: PubMed
    68. Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res. 2008 Jan 15; 14(2):589-96. PMID: 18223235.
      View in: PubMed
    69. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42. PMID: 17199433.
      View in: PubMed
    70. Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30. PMID: 17062760.
      View in: PubMed
    71. Haugen BR. Does the metabolic activity of metastatic thyroid carcinoma correlate with prognosis? Nat Clin Pract Endocrinol Metab. 2006 Sep; 2(9):488-9. PMID: 16957760.
      View in: PubMed
    72. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug; 45(8):613-26. PMID: 16788983; PMCID: PMC1899163.
    73. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13; 25(16):2304-17. PMID: 16331265.
      View in: PubMed
    74. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54. PMID: 16595499.
      View in: PubMed
    75. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006 Feb; 16(2):109-42. PMID: 16420177.
      View in: PubMed
    76. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar; 91(3):878-84. PMID: 16394083.
      View in: PubMed
    77. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32. PMID: 16384850.
      View in: PubMed
    78. Sharma V, Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology. 2006 Mar; 147(3):1438-51. PMID: 16306084.
      View in: PubMed
    79. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, Sukumar S, Sidransky D. Tumor-specific changes in mtDNA content in human cancer. Int J Cancer. 2005 Oct 10; 116(6):920-4. PMID: 15856456.
      View in: PubMed
    80. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004 Oct; 122(4):524-31. PMID: 15487449.
      View in: PubMed
    81. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep; 4(3):175-80. PMID: 15379720.
      View in: PubMed
    82. Woodmansee WW, Haugen BR. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf). 2004 Aug; 61(2):163-73. PMID: 15272910.
      View in: PubMed
    83. Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab. 2004 Aug; 89(8):3665-7. PMID: 15292284.
      View in: PubMed
    84. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther. 2004 Aug; 3(8):1011-20. PMID: 15299084.
      View in: PubMed
    85. Haugen BR, Jensen DR, Sharma V, Pulawa LK, Hays WR, Krezel W, Chambon P, Eckel RH. Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology. 2004 Aug; 145(8):3679-85. PMID: 15087432.
      View in: PubMed
    86. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab. 2004 Jan; 89(1):272-80. PMID: 14715861.
      View in: PubMed
    87. McDermott MT, Woodmansee WW, Haugen BR, Smart A, Ridgway EC. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid. 2003 Dec; 13(12):1133-9. PMID: 14751034.
      View in: PubMed
    88. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Apr; 88(4):1433-41. PMID: 12679418.
      View in: PubMed
    89. McDermott MT, Haugen BR, Black JN, Wood WM, Gordon DF, Ridgway EC. Congenital isolated central hypothyroidism caused by a "hot spot" mutation in the thyrotropin-beta gene. Thyroid. 2002 Dec; 12(12):1141-6. PMID: 12593729.
      View in: PubMed
    90. McDermott NB, Gordon DF, Kramer CA, Liu Q, Linney E, Wood WM, Haugen BR. Isolation and functional analysis of the mouse RXRgamma1 gene promoter in anterior pituitary cells. J Biol Chem. 2002 Sep 27; 277(39):36839-44. PMID: 12114515.
      View in: PubMed
    91. Sugawara M, Matsuzuka F, Fukata S, Kuma K, Moatamed F, Haugen BR. Excessive survivin expression in thyroid lymphomas. Hum Pathol. 2002 May; 33(5):524-7. PMID: 12094378.
      View in: PubMed
    92. Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf). 2002 Mar; 56(3):281-90. PMID: 11940037.
      View in: PubMed
    93. Lehner R, Enomoto T, McGregor JA, Shroyer L, Haugen BR, Pugazhenthi U, Shroyer KR. Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstet Gynecol Scand. 2002 Feb; 81(2):162-7. PMID: 11942908.
      View in: PubMed
    94. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, Shroyer KR. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol. 2002 Jan; 84(1):120-5. PMID: 11748987.
      View in: PubMed
    95. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002 Jan; 12(1):37-43. PMID: 11838729.
      View in: PubMed
    96. McDermott MT, Haugen BR, Lezotte DC, Seggelke S, Ridgway EC. Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients. Thyroid. 2001 Aug; 11(8):757-64. PMID: 11525268.
      View in: PubMed
    97. Haugen BR, Lin EC. Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am. 2001 Jun; 30(2):469-92. PMID: 11444171.
      View in: PubMed
    98. Haugen BR. The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated. Thyroid. 2000 Nov; 10(11):971-3. PMID: 11128724.
      View in: PubMed
    99. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, Jensen DR, Eckel RH, Krezel W, Chambon P, Haugen BR. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J Clin Invest. 2000 Jul; 106(1):73-9. PMID: 10880050; PMCID: PMC314362.
    100. Haugen BR. Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):139-45. PMID: 11704999.
      View in: PubMed
    101. McDermott MT, Haugen BR, Gordon DF, Wood WM, Brown NS, Bauer CA, Garrity MJ, Kleinschmidt-DeMasters BK, Lillehei KO, Samuels MH, Bright TM, Ridgway EC. Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors. Pituitary. 1999 Nov; 2(3):217-24. PMID: 11081157.
      View in: PubMed
    102. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov; 84(11):3877-85. PMID: 10566623.
      View in: PubMed
    103. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999 Apr 08; 340(14):1075-9. PMID: 10194237.
      View in: PubMed
    104. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999 Jan-Feb; 16(1):34-41. PMID: 9890738.
      View in: PubMed
    105. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998 Oct 15; 129(8):622-7. PMID: 9786809.
      View in: PubMed
    106. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998 Sep 01; 83(5):1012-21. PMID: 9731906.
      View in: PubMed
    107. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998 Sep; 8(9):737-44. PMID: 9777742.
      View in: PubMed
    108. Yost TJ, Jensen DR, Haugen BR, Eckel RH. Effect of dietary macronutrient composition on tissue-specific lipoprotein lipase activity and insulin action in normal-weight subjects. Am J Clin Nutr. 1998 Aug; 68(2):296-302. PMID: 9701186.
      View in: PubMed
    109. Gordon DF, Lewis SR, Haugen BR, James RA, McDermott MT, Wood WM, Ridgway EC. Pit-1 and GATA-2 interact and functionally cooperate to activate the thyrotropin beta-subunit promoter. J Biol Chem. 1997 Sep 26; 272(39):24339-47. PMID: 9305891.
      View in: PubMed
    110. Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR. Telomerase activity in benign and malignant thyroid tumors. Thyroid. 1997 Jun; 7(3):337-42. PMID: 9226200.
      View in: PubMed
    111. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC. The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. Mol Endocrinol. 1997 Apr; 11(4):481-9. PMID: 9092800.
      View in: PubMed
    112. Wood WM, Dowding JM, Bright TM, McDermott MT, Haugen BR, Gordon DF, Ridgway EC. Thyroid hormone receptor beta2 promoter activity in pituitary cells is regulated by Pit-1. J Biol Chem. 1996 Sep 27; 271(39):24213-20. PMID: 8798664.
      View in: PubMed
    113. Haugen BR, McDermott MT, Gordon DF, Rupp CL, Wood WM, Ridgway EC. Determinants of thyrotrope-specific thyrotropin beta promoter activation. Cooperation of Pit-1 with another factor. J Biol Chem. 1996 Jan 05; 271(1):385-9. PMID: 8550592.
      View in: PubMed
    114. Ng L, Forrest D, Haugen BR, Wood WM, Curran T. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone. Mol Endocrinol. 1995 Sep; 9(9):1202-13. PMID: 7491112.
      View in: PubMed
    115. Lossie AC, Haugen BR, Wood WM, Camper SA, Gordon DF. Chromosomal localization of the large subunit of mouse replication factor C in the mouse and human. Mamm Genome. 1995 Jan; 6(1):58-9. PMID: 7719032.
      View in: PubMed
    116. Wood WM, Dowding JM, Haugen BR, Bright TM, Gordon DF, Ridgway EC. Structural and functional characterization of the genomic locus encoding the murine beta 2 thyroid hormone receptor. Mol Endocrinol. 1994 Dec; 8(12):1605-17. PMID: 7708051.
      View in: PubMed
    117. Haugen BR, Gordon DF, Nelson AR, Wood WM, Ridgway EC. The combination of Pit-1 and Pit-1T have a synergistic stimulatory effect on the thyrotropin beta-subunit promoter but not the growth hormone or prolactin promoters. Mol Endocrinol. 1994 Nov; 8(11):1574-82. PMID: 7877626.
      View in: PubMed
    118. Haugen BR, Nawaz S, Cohn A, Shroyer K, Bunn PA, Liechty DR, Ridgway EC. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid. 1994; 4(3):297-300. PMID: 7833666.
      View in: PubMed
    119. Haugen BR, Wood WM, Gordon DF, Ridgway EC. A thyrotrope-specific variant of Pit-1 transactivates the thyrotropin beta promoter. J Biol Chem. 1993 Oct 05; 268(28):20818-24. PMID: 8407911.
      View in: PubMed
    120. Gordon DF, Haugen BR, Sarapura VD, Nelson AR, Wood WM, Ridgway EC. Analysis of Pit-1 in regulating mouse TSH beta promoter activity in thyrotropes. Mol Cell Endocrinol. 1993 Oct; 96(1-2):75-84. PMID: 8276142.
      View in: PubMed
    Haugen's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)